New drug combo shows promise for Tough-to-Treat colorectal cancer
NCT ID NCT04868773
First seen Apr 26, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This early-phase study tested a combination of two drugs, cabozantinib and TAS-102, in 15 people with metastatic colorectal cancer that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. The study is complete and helps guide future research on this drug pair.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, 92868, United States
Conditions
Explore the condition pages connected to this study.